Pharma's Most Infamous Bad Boy Can't Stop Breaking the Rules
Martin Shkreli was banned from pharma for life. The FTC says he responded by trading 60+ pharma stocks, livestreaming his moves, and shorting biotech companies on camera. Now regulators want him held in contempt.
Martin Shkreli was banned from the pharmaceutical industry for life. That was supposed to be the end of the story. It wasn't.
The FTC and seven state attorneys general just asked a federal judge to hold Shkreli in civil contempt, alleging that the man once dubbed "Pharma Bro" has been flagrantly ignoring his lifetime ban since the day he walked out of prison. The accusations read like someone who got kicked out of a casino and snuck back in through every possible entrance.
The Ban That Was Supposed to Stick
A quick refresher on how we got here. Back in 2015, Shkreli's company Turing Pharmaceuticals (later renamed Vyera) bought Daraprim, a drug used to treat a potentially fatal parasitic infection. Then they jacked the price from $13.50 to $750 per tablet. That's a roughly 5,000% increase, practically overnight.
The public outrage was immediate and intense. But the legal case wasn't about price gouging per se. The FTC and states argued that Shkreli orchestrated an anticompetitive scheme: restricting access to drug samples so generic competitors couldn't enter the market, locking down distribution channels, and doing everything possible to protect that inflated price from competition.
In January 2022, U.S. District Judge Denise Cote agreed. She called his conduct "egregious, deliberate, repetitive, long-running, and ultimately dangerous." The punishment was historic: a lifetime ban from the pharmaceutical industry and $64.6 million in disgorgement (fancy legal speak for "give back the money you made"). The Second Circuit upheld the whole thing in January 2024.
So that was that. Shkreli was done with pharma. Or pharma was done with him. In theory.
The World's Least Subtle Violations
Here's where it gets almost comical. The lifetime ban didn't just prohibit Shkreli from running a drug company. It barred him from participating in the industry "in any manner," including owning pharmaceutical stock or taking actions to influence a pharma company's management or business. Directly or indirectly. Full stop.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
According to the FTC's filing, Shkreli responded to this crystal-clear prohibition by trading shares in at least 60 pharmaceutical companies. We're not talking about some obscure biotech micro-caps buried in a retirement account. The filing names Pfizer, Moderna, Eli Lilly, and Novo Nordisk among the companies whose stock he allegedly traded.
And he wasn't quiet about it. Regulators allege he livestreamed his trading activity, posted commentary about drug companies on YouTube, X, and Reddit, and encouraged followers to invest based on his recommendations. It's like someone on a restraining order showing up at their ex's house and filming a TikTok about it.
The specifics paint a picture of escalation. In 2024, he allegedly shorted Cassava Sciences around the time the Alzheimer's-focused biotech reported disappointing clinical trial results. In 2025, he reportedly bet against Capricor Therapeutics, a company developing a treatment for Duchenne muscular dystrophy. By 2026, regulators say he launched a trading challenge using a $10 million account, openly discussing his strategies and views on drug companies while livestreaming to an audience.
Can You Actually Police a Lifetime Ban?
This case raises a fascinating question that goes well beyond one man's inability to follow court orders. Can lifetime industry bans actually be enforced?
The answer, so far, is: yes, but only if someone is watching. And only if the violations have real consequences.
FTC Commissioner Mark Meador said Shkreli "repeatedly ignored" the injunction, describing his conduct as a "deliberate pattern of defiance." The Commission is now asking the court for disgorgement of all profits Shkreli made from pharmaceutical stock trading since February 2022, plus forced divestiture of any remaining pharma holdings.
The irony is that Shkreli's own public behavior made the enforcement case relatively straightforward. When your alleged violations include YouTube livestreams and Reddit posts, regulators don't need to subpoena hidden bank records. The evidence is sitting right there, timestamped and archived.
But that's also the exception, not the rule. Most people violating an industry ban wouldn't advertise it to an internet audience. The FTC previously ran into this problem in 2023, when it sought contempt after Shkreli allegedly failed to provide documents about a company called Druglike, Inc. Indirect participation through consultants, nominees, or informal influence channels is much harder to detect.
The Bigger Picture for Pharma Enforcement
Lifetime bans are rare. The Shkreli case was the FTC's marquee example of holding an individual personally accountable for anticompetitive conduct, not just the company. It was supposed to send a message: if you weaponize a monopoly to gouge patients, the consequences follow you, not just the corporate entity that can be dissolved, renamed, or sold.
That message only works if the ban has teeth. The contempt proceeding is, in some ways, more important than the original case. If Shkreli can publicly trade pharma stocks, short biotech companies, and broadcast industry commentary without facing meaningful penalties, the lifetime ban becomes a piece of paper.
Regulators seem aware of the stakes. The filing reportedly proposes "clear and escalating consequences" for future violations, suggesting they want a framework that makes each subsequent breach more painful.
What Happens Next
It's worth noting that these are allegations in a contempt motion, not a final ruling. A judge will need to determine whether Shkreli's specific actions actually violated the injunction's terms. His defense could argue that buying stock in Pfizer isn't the same as "participating in the pharmaceutical industry" in any meaningful sense.
But the breadth of the alleged conduct makes that a tough sell. Sixty companies, multiple livestreams, public investment recommendations, and a $10 million trading account don't exactly scream "passive bystander."
Shkreli has always been pharma's villain who craves the spotlight. That instinct made him infamous. Now it might make the FTC's case a whole lot easier to prove.
Funding & Financings5 min read
RNAi's Biggest Problem Just Got a $200 Million Bet
City Therapeutics just raised $200 million in an upsized IPO to crack RNAi's hardest problem: getting gene-silencing drugs to work outside the liver. With a team of Alnylam alumni and nearly half a billion in total funding, they're making the biggest bet yet on extrahepatic delivery.
